Sign In
Buy VNDA
$5.10
-0.0800 (-1.54%)
At Close: Jul 31, 2026
What's Going On With Vanda Pharmaceuticals Stock Wednesday?
03:07pm, Wednesday, 31'st Dec 2025
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion.
Vanda Pharma's (VNDA) NEREUS Approval Boosts Growth Prospects
11:14am, Wednesday, 31'st Dec 2025
Vanda Pharma (VNDA) has reached multi-year highs following the FDA's approval of NEREUS, a treatment for motion-induced vomiting. This approval marks a signific
Vanda Jumps 21% After FDA Approves Motion Sickness Therapy
10:57am, Wednesday, 31'st Dec 2025
Vanda Pharmaceuticals (VNDA) jumped roughly 21% in premarket trading after the U.S. Food and Drug Administration approved its motion sickness therapy Nereus, al
Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval
10:57am, Wednesday, 31'st Dec 2025
The FDA approved Vanda's drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.
VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains
08:40am, Wednesday, 31'st Dec 2025
Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.
Stock Market Today: S&P 500, Dow Jones Futures Down As Santa Rally Hopes Fade—Investors Await Initial Jobless Claims Report
04:09am, Wednesday, 31'st Dec 2025
Stock futures are in red early morning on New Year's Eve, after markets ended lower on Tuesday, as hopes of Santa Claus rally begin to fade.
Vanda Pharmaceuticals, One Stop Systems And 3 Stocks To Watch Heading Into Wednesday
01:19am, Wednesday, 31'st Dec 2025
Stock futures down, ORIS to acquire controlling stake in tea company, VNDA gets FDA approval, ELLO posts strong earnings.
US FDA approves Vanda Pharmaceuticals' motion sickness drug
06:30pm, Tuesday, 30'th Dec 2025
Vanda Pharmaceuticals said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health regulator, becoming the first treatment for the condition to receive the no
WASHINGTON, Dec. 30, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an o
3 Biotech Stocks With Major 2026 Catalysts
10:15am, Monday, 29'th Dec 2025
Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.
Vanda Pharmaceuticals Stock Rallies on FDA Filing
11:41am, Friday, 26'th Dec 2025
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are up 2.2% to trade at $7.06 at last check.
Squarepoint Ops LLC Has $724,000 Position in Vanda Pharmaceuticals Inc. $VNDA
05:08am, Wednesday, 24'th Dec 2025
Squarepoint Ops LLC raised its holdings in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) by 96.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi
WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administ
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
05:02pm, Thursday, 11'th Dec 2025
WASHINGTON , Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
04:21pm, Thursday, 04'th Dec 2025
WASHINGTON , Dec. 4, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on protocol VP
